News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Extab and Sopharma Release: Tabex Shown to be a Highly Cost Effective Treatment for Smoking Cessation


1/9/2012 6:45:28 AM

WILMINGTON, Del. & LONDON--(BUSINESS WIRE)--Extab Corporation (“Extab”) a clinical stage biopharmaceutical company with a focus on smoking cessation, today announced the results of a cost effectiveness study published in the peer reviewed journal, Nicotine and Tobacco Research. These data are based on the results of the Tabex Smoking Cessation (“TASC”) 740-patient pivotal trial, which were published in the New England Journal of Medicine on September 29, 2011.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES